COMMUNIQUÉS West-GlobeNewswire

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

02/05/2024 - 22:30

BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

02/05/2024 - 22:30

NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell [...]

Spectral AI to Participate at the Sidoti Micro-Cap Virtual Investor Conference

02/05/2024 - 22:15

DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

02/05/2024 - 22:10

ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today [...]

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

02/05/2024 - 22:10

- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . ( [...]

Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights

02/05/2024 - 22:05

Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026 CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. ( [...]

LeMaitre Q1 2024 Financial Results

02/05/2024 - 22:05

BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly dividend and provided [...]

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/05/2024 - 22:05

CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today [...]

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

02/05/2024 - 22:05

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. [...]

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

02/05/2024 - 22:05

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory [...]

Kura Oncology Reports First Quarter 2024 Financial Results

02/05/2024 - 22:05

– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive preliminary combination data [...]

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

02/05/2024 - 22:05

Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage [...]

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

02/05/2024 - 22:05

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will [...]

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

02/05/2024 - 22:05

- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program [...]

Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024

02/05/2024 - 22:05

-- Conference call and webcast to begin at 4:30pm ET -- EMERYVILLE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most [...]

QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications

02/05/2024 - 22:05

QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine [...]

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

02/05/2024 - 22:05

Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of [...]

The Joint Corp. Reports First Quarter 2024 Financial Results

02/05/2024 - 22:05

- Grew Q1 2024 Revenue 5%, System-wide Sales 9%, and System-wide Comp Sales 3% vs. Q1 2023 - - Opened 23 Franchised Clinics, Increasing Clinic Count to 954 at March 31, 2024 - - Sold 15 Franchise Licenses, Tripling [...]

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

02/05/2024 - 22:05

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to [...]